Free Alerts   Login
Health Care › Pharmaceutical Preparations

SIGA Stock Price Correlated With SIGA Technologies Financials

SIGA Stock Price vs. Quarterly
SIGA
Income Statement
Cash Flow
Balance Sheet

SIGA Income Statement

Enable JavaScript and reload
Revenue, Net:
Revenue Per Share:
Cost of Goods & Services Sold:
Gross Profit:
Selling, General & Admin Expense:
Research & Development Expense:
Total Operating Expenses:
Operating Income:
Income Taxes:
Net Income:
Earnings Per Share, Diluted:
Earnings Per Share, Basic:
Shares Outstanding, Basic Avg:
Shares Outstanding, Diluted Avg:
Common Stock Shares Outstanding:

SIGA Cash Flow

Enable JavaScript and reload
Operating Activities Net Income:
Depreciation, Depletion & Amortization:
Change in Accounts Receiveable:
Net Cash from Operations:
Net Cash from Operations Per Share:
Repurchases/Buybacks Common Stock:
Issuance of Long-term Debt:
Cash Dividends Paid:
Net Cash from Financing Activities:
Property, Plant & Equipment Purchases:
Purchases of Businesses, Net of Cash:
Net Cash from Investing Activities:
Net Change in Cash & Equivalents:

SIGA Balance Sheet

Enable JavaScript and reload
Cash and Cash Equivalents:
Short-Term Investments:
Accounts Receivable, Net:
Inventories:
Total Current Assets:
Property, Plant & Equipment, Net:
Total Assets:
Accounts Payable:
Current Portion of Long-Term Debt:
Total Short-Term Liabilities:
Long Term Debt, Non-Current Portion:
Total Long-Term Liabilities:
Total Liabilities:

Major Holders (from 13F filings)

Investment Type
Change
Value (x$1000)
increase or decrease
Blackrock.
3,513,890 sh
149,578 sh
4%
$19,678
$2,016
Federated Hermes.
3,219,848 sh
-1,143,392 sh
-26%
$18,031
-$4,876
First Wilshire Securities Management
2,362,107 sh
297,095 sh
14%
$13,228
$2,387
Kempen Capital Management N.V.
2,274,359 sh
343,599 sh
18%
$12,736
$2,600
Vanguard Group
2,242,097 sh
39,220 sh
2%
$12,555
$990
Altravue Capital
2,043,196 sh
-64,360 sh
-3%
$11,442
$377
Royce & Associates Lp
1,756,311 sh
429,500 sh
32%
$9,835
$2,869
Dimensional Fund Advisors
1,698,154 sh
226,187 sh
15%
$9,510
$1,782
Goldman Sachs Group
1,647,455 sh
-658,770 sh
-29%
$9,226
-$2,882
State Street
1,053,860 sh
53,369 sh
5%
$5,902
$649
Hotchkis & Wiley Capital Management
1,024,960 sh
595,856 sh
139%
$5,740
$3,487
Geode Capital Management
1,021,653 sh
53,138 sh
5%
$5,722
$637
Jupiter Asset Management
1,003,981 sh
 
$5,622
General American Investors Co
793,042 sh
-178,089 sh
-18%
$4,441
-$657
D. E. Shaw & Co..
711,729 sh
-83,953 sh
-11%
$3,986
-$191
Uniplan Investment Counsel.
571,677 sh
148,621 sh
35%
$3,224
$1,008
Northernrp
490,231 sh
24,615 sh
5%
$2,745
$301
Price Jennifer C.
458,700 sh
 
$2,569
Legato Capital Management
403,087 sh
 
$2,257
Morgan Stanley
402,873 sh
230,622 sh
134%
$2,255
$1,350
COMPANY PROFILE
1. Organization and Basis of Presentation

Description of Business
SIGA Technologies, Inc. (“SIGA” or the “Company”) is a commercial-stage pharmaceutical company. The Company's lead product, TPOXX® (“oral TPOXX®”) is a United States Food & Drug Administration ("FDA")-approved oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. On July 13, 2018, the FDA approved oral TPOXX®.

Oral TPOXX® is a novel, patented drug that is easy to store, transport and administer. Oral TPOXX® labeling, approved by the FDA, limits sales of oral TPOXX® in the U.S. to those for the U.S. Strategic National Stockpile ("Strategic Stockpile"). The Company has been delivering oral TPOXX® to the Strategic Stockpile since 2013.

On December 1, 2021, the Company announced that Health Canada approved oral tecovirimat as an extraordinary use drug.

On January 10, 2022, a Marketing Authorisation Application ("MAA") with the European Medicines Agency ("EMA") for oral tecovirimat was approved. The MAA was filed under the centralized application process, which authorized the sale of oral tecovirimat in European Union member states, as well as Norway (which granted separate follow-on approval), Iceland, and Liechtenstein. The EMA approved label indication covers the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox.

With respect to the regulatory approvals by Health Canada and the EMA, oral tecovirimat represents the same formulation that was approved by the FDA in July 2018 under the brand name TPOXX®.

Free historical financial statements for SIGA Technologies Inc.. See how revenue, income, cash flow, and balance sheet financials have changed over 28 quarters since 2017. Compare with SIGA stock chart to see long term trends.

Data imported from SIGA Technologies Inc. SEC filings. Check original filings before making any investment decision.